All Oncology News

The second-line setting for HER2-mutated NSCLC is shifting with TKIs looking to demonstrate efficacy and T-DXd under examination in the frontline now.

The Fortel PSA Screening Test has been approved by the United Arab Emirates MOHAP for the rapid detection of early signs of prostate cancer.

Preliminary data show that AVA6000 led to robust and clinically meaningful tumor shrinkage in patients with salivary gland cancer.

First-line IMM-1-104 plus chemotherapy produced responses and disease control in patients with pancreatic cancer.

Health Canada approved fruquintinib for select patients with metastatic colorectal cancer.

The FDA has granted a breakthrough device designation to the DCISionRT test for patients with breast cancer with ductal carcinoma in situ.

Frontline dostarlimab plus chemotherapy has been approved in the EU for all adult patients with primary advanced or recurrent endometrial cancer.

The development of LAVA-1207 for metastatic castration-resistant prostate cancer has been discontinued.

Laboratory research led by Anna Bianchi-Smiraglia, PhD, reveals therapeutic target in metabolic enzyme IMPDH2.

The FDA has granted 510(k) clearance for the Ventana Kappa and Lambda Dual ISH mRNA Probe Cocktail, an assay designed to assist pathologists in diagnosing B-cell lymphoma

ELC-100 has been granted orphan drug designation by the FDA for the treatment of patients with pancreatic neuroendocrine tumors.

Ira Zackon, MD, discusses real-world observational data on bispecific antibody use in community oncology in patients with relapsed/refractory multiple myeloma.

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.

The addition of pembrolizumab to preoperative radiation therapy followed by surgery prolonged DFS in patients with soft tissue sarcoma of the extremity.

Treatment with avapritinib was associated with dynamic changes in bone density based on lumbar T-scores among patients with systemic mastocytosis.

Qing Chen, MD, PhD, has joined as a new assistant professor in the Cancer Signaling and Microenvironment Research Program.

The FDA approved datopotamab deruxtecan for select unresectable or metastatic, hormone receptor–positive, HER2-negative breast cancer.

Senaparib has received marketing authorization in China as a first-line maintenance therapy for advanced ovarian cancer.

Limertinib was approved in China for locally advanced or metastatic non–small cell lung cancer harboring an EGFR T790M mutation.

David S. Siegel, MD, PhD, discusses early safety and efficacy data that support further development of mezigdomide-based combinations in multiple myeloma.

LOAd703 has been granted FDA fast track designation for the treatment of patients with pancreatic cancer.

Alberto Montero, MD, MBA, CPHQ, discusses early signals of efficacy and safety with zanidatamab plus evorpacept in HER2-positive and -low breast cancer.

The FDA approved sotorasib plus panitumumab for adult select patients with KRAS G12C–mutated metastatic colorectal cancer.

The FDA has approved acalabrutinib plus bendamustine and rituximab for adult patients with previously untreated MCL who are ineligible for autologous HSCT.

Breelyn Wilky, MD, discusses the importance of disease screening and early diagnosis in the treatment of patients with sarcoma.

Obe-cel generated durable remissions in patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated during the FELIX trial.

The FDA granted breakthrough therapy designation to lete-cel for patients with unresectable or metastatic myxoid/round cell liposarcoma.

Dana-Farber Cancer Institute and Gustave Roussy have announced that the topic of the Fourth Transatlantic Exchange in Oncology Conference will be “Radiopharmaceutical Therapy Meets Oncology.”

The FDA issued a CRL to the BLA of tabelecleucel in EBV+ PTLD following at least 1 prior line of treatment.

Nogapendekin alfa inbakicept MAAs have been submitted to the EU's EMA and the UK's MHRA for BCG-unresponsive non–muscle-invasive bladder cancer.